We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Guidance on the collection, verification, and reporting of safety events in clinical trials of an investigational medicinal product.
How to report adverse incidents involving insulin infusion pumps and integrated meter systems under the vigilance system.
The MHRA produces over 95 per cent of the World Health Organization’s (WHO) biological standards.
Report diabetes treated with Sulphonylureas or Glinide tablets to DVLA if you're a lorry, bus or coach driver.
Guidance on the safe and effective use of GLP-1 medicines for weight loss and diabetes.
The MHRA has today, 26 November 2025, approved inavolisib (Itovebi) for the treatment of adults with a type of breast cancer called HR-positive
Scottish patients placed at the heart of a multi-million pound study of weight-loss medicines.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).